$TDOC
Teladoc Health, Inc.

2023 Q4 Form 10-Q Financial Statement

#000147744923000066 Filed on October 27, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $660.5M $660.2M $611.4M
YoY Change 3.58% 7.99% 17.2%
Cost Of Revenue $193.4M $186.0M $185.6M
YoY Change 2.41% 0.21% 9.81%
Gross Profit $467.1M $474.3M $425.8M
YoY Change 4.07% 11.39% 20.75%
Gross Profit Margin 70.72% 71.84% 69.64%
Selling, General & Admin $309.6M $168.0M $346.1M
YoY Change -4.53% -51.45% 108.97%
% of Gross Profit 66.27% 35.43% 81.28%
Research & Development $89.94M $84.29M $87.82M
YoY Change 15.94% -4.02% 9.43%
% of Gross Profit 19.25% 17.77% 20.62%
Depreciation & Amortization $98.17M $94.30M $62.71M
YoY Change 28.52% 50.39% 20.81%
% of Gross Profit 21.02% 19.88% 14.73%
Operating Expenses $497.0M $252.3M $495.9M
YoY Change 4.08% -49.12% 101.7%
Operating Profit -$29.92M -$64.73M -$70.14M
YoY Change 4.26% -7.72% 15.78%
Interest Expense $8.169M $5.646M -$1.346M
YoY Change 331.54% -519.47% -92.88%
% of Operating Profit
Other Income/Expense, Net $1.537M -$1.792M -$1.571M
YoY Change -12.07% 14.07% 317.82%
Pretax Income -$25.38M -$59.56M -$74.65M
YoY Change -99.33% -20.22% -7.5%
Income Tax $3.515M -$2.484M -$1.171M
% Of Pretax Income
Net Earnings -$28.89M -$57.07M -$73.48M
YoY Change -99.24% -22.32% -12.88%
Net Earnings / Revenue -4.37% -8.64% -12.02%
Basic Earnings Per Share -$0.35 -$0.45
Diluted Earnings Per Share -$0.17 -$0.35 -$454.3K
COMMON SHARES
Basic Shares Outstanding 165.6M shares 165.0M shares 161.7M
Diluted Shares Outstanding 165.1M shares 161.7M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $1.124B $1.031B $899.6M
YoY Change 22.38% 14.6% 8.87%
Cash & Equivalents $1.124B $1.031B $899.6M
Short-Term Investments $0.00
Other Short-Term Assets $7.443M $8.307M $126.9M
YoY Change -38.51% -93.45% 32.28%
Inventory $29.51M $35.92M $59.34M
Prepaid Expenses $65.65M $62.25M $59.14M
Receivables $217.4M $205.9M $201.7M
Other Receivables $12.64M $12.88M $0.00
Total Short-Term Assets $1.489B $1.387B $1.288B
YoY Change 13.2% 7.73% 11.26%
LONG-TERM ASSETS
Property, Plant & Equipment $32.03M $32.89M $72.46M
YoY Change 8.07% -54.61% 168.09%
Goodwill $1.073B $1.073B $4.846B
YoY Change 0.0% -77.85% -66.51%
Intangibles $1.678B $1.728B $1.854B
YoY Change -8.66% -6.79% -4.02%
Long-Term Investments
YoY Change
Other Assets $80.26M $74.45M $43.66M
YoY Change 65.34% 70.54% 144.02%
Total Long-Term Assets $2.903B $2.941B $6.816B
YoY Change -4.18% -56.86% -58.68%
TOTAL ASSETS
Total Short-Term Assets $1.489B $1.387B $1.288B
Total Long-Term Assets $2.903B $2.941B $6.816B
Total Assets $4.392B $4.328B $8.104B
YoY Change 1.08% -46.59% -54.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $43.64M $26.00M $70.78M
YoY Change -8.5% -63.27% 104.25%
Accrued Expenses $281.3M $225.0M $240.3M
YoY Change 45.43% -6.38% 59.23%
Deferred Revenue $95.66M $99.19M
YoY Change -6.06%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $10.09M
YoY Change
Total Short-Term Liabilities $420.6M $402.6M $411.4M
YoY Change 5.21% -2.13% 36.18%
LONG-TERM LIABILITIES
Long-Term Debt $1.539B $1.538B $1.542B
YoY Change -0.3% -0.28% 26.32%
Other Long-Term Liabilities $1.080M $1.693M $45.86M
YoY Change -33.25% -96.31% 3353.16%
Total Long-Term Liabilities $1.080M $1.693M $1.588B
YoY Change -33.25% -99.89% 119490.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $420.6M $402.6M $411.4M
Total Long-Term Liabilities $1.080M $1.693M $1.588B
Total Liabilities $421.7M $404.3M $2.051B
YoY Change 5.06% -80.29% 576.03%
SHAREHOLDERS EQUITY
Retained Earnings -$15.23B -$15.20B -$11.20B
YoY Change 1.47% 35.73% 693.94%
Common Stock $17.59B $17.54B $17.30B
YoY Change 1.34% 1.36% -0.57%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.326B $2.294B $6.053B
YoY Change
Total Liabilities & Shareholders Equity $4.392B $4.328B $8.104B
YoY Change 1.08% -46.59% -54.09%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income -$28.89M -$57.07M -$73.48M
YoY Change -99.24% -22.32% -12.88%
Depreciation, Depletion And Amortization $98.17M $94.30M $62.71M
YoY Change 28.52% 50.39% 20.81%
Cash From Operating Activities $130.1M $105.6M $63.02M
YoY Change 98.51% 67.56% -17.72%
INVESTING ACTIVITIES
Capital Expenditures $36.55M $37.60M -$43.21M
YoY Change -32.18% -187.03% 186.13%
Acquisitions
YoY Change
Other Investing Activities $1.000K $0.00 $1.757M
YoY Change -100.0% -108.96%
Cash From Investing Activities -$36.55M -$37.60M -$41.45M
YoY Change -32.18% -9.28% 19.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.746M 5.000M 634.0K
YoY Change -139.85% 688.64% -19.13%
NET CHANGE
Cash From Operating Activities 130.1M 105.6M 63.02M
Cash From Investing Activities -36.55M -37.60M -41.45M
Cash From Financing Activities -1.746M 5.000M 634.0K
Net Change In Cash 91.83M 73.00M 22.21M
YoY Change 472.53% 228.73% -47.95%
FREE CASH FLOW
Cash From Operating Activities $130.1M $105.6M $63.02M
Capital Expenditures $36.55M $37.60M -$43.21M
Free Cash Flow $93.57M $68.00M $106.2M
YoY Change 702.65% -35.99% 15.85%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1941888000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1769131000 usd
CY2023Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
186152000 usd
CY2022Q3 us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
178920000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
541698000 usd
us-gaap Marketing And Advertising Expense
MarketingAndAdvertisingExpense
477094000 usd
CY2023Q3 us-gaap Selling Expense
SellingExpense
52309000 usd
CY2022Q3 us-gaap Selling Expense
SellingExpense
54634000 usd
us-gaap Selling Expense
SellingExpense
160329000 usd
us-gaap Selling Expense
SellingExpense
170893000 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84289000 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84590000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
258583000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
250698000 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
115716000 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
112090000 usd
CY2023Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5824000 usd
CY2022Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1594000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
16848000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
8993000 usd
CY2023Q3 us-gaap Restructuring Costs
RestructuringCosts
411000 usd
CY2022Q3 us-gaap Restructuring Costs
RestructuringCosts
3677000 usd
us-gaap Restructuring Costs
RestructuringCosts
16043000 usd
us-gaap Restructuring Costs
RestructuringCosts
3677000 usd
CY2023Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
94302000 usd
CY2022Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
62008000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
239550000 usd
us-gaap Depreciation And Amortization
DepreciationAndAmortization
180312000 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000 usd
CY2023Q3 us-gaap Costs And Expenses
CostsAndExpenses
724963000 usd
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
683132000 usd
us-gaap Costs And Expenses
CostsAndExpenses
2155360000 usd
us-gaap Costs And Expenses
CostsAndExpenses
11606792000 usd
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-64725000 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-71730000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-213472000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-9837661000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12606000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4803000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1971000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-57073000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73476000 usd
us-gaap Net Income Loss
NetIncomeLoss
-191478000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9849460000 usd
CY2023Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-2740000 usd
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-19402000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
1256000 usd
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-42981000 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92878000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-190222000 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9892441000 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.35
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.35
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.45
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.45
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.17
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-61.09
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-61.09
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161727962 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161727962 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
164079194 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
164079194 shares
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
2295144000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.6822
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0368
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0434
CY2021 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2023#AccountingStandardsUpdate202006Member
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P3M
CY2023Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2023Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20230930#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://www.teladoc.com/20230930#AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
CY2023Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
185960000 usd
CY2022Q3 us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
185619000 usd
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
566607000 usd
us-gaap Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
555114000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
355702000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
330011000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
33075000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
6192000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
5646000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
6149000 usd
us-gaap Interest Expense
InterestExpense
16744000 usd
us-gaap Interest Expense
InterestExpense
17355000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1792000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1571000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2908000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2607000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59557000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74647000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-194233000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9851431000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2484000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1171000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2755000 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-59813000 usd
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
165119379 shares
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
165119379 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
161217033 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
161217033 shares
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
746000 usd
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
0 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
57973000 usd
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2740000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-57073000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2294050000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
2307745000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1423000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
5790000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
169314000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1256000 usd
us-gaap Net Income Loss
NetIncomeLoss
-191478000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
2294050000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
6084650000 usd
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
666000 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
60223000 usd
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-19402000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73476000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6052661000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
16045757000 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5646000 usd
us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4225000 usd
us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
7000 usd
us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt Subsequent Adjustments
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebtSubsequentAdjustments
2000 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
180502000 usd
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-42981000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9849460000 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
6052661000 usd
us-gaap Net Income Loss
NetIncomeLoss
-191478000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9849460000 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
239550000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
180312000 usd
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
1965000 usd
tdoc Depreciation Of Rental Equipment
DepreciationOfRentalEquipment
2185000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
8325000 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
9266000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
4935000 usd
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
8867000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
154727000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
167098000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-6658000 usd
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-5942000 usd
tdoc Accretion Of Interest
AccretionOfInterest
2545000 usd
tdoc Accretion Of Interest
AccretionOfInterest
2496000 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
0 usd
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2507000 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
0 usd
us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
-2514000 usd
us-gaap Nature Of Operations
NatureOfOperations
Organization and Description of Business<div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Teladoc Health, Inc., together with its subsidiaries, is referred to herein as “Teladoc Health,” or the “Company,” and is the global leader in whole person virtual care focusing on forging a new healthcare experience with better convenience, outcomes, and value around the world. The Company’s mission is to empower all people everywhere to live their healthiest lives by transforming the healthcare experience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was incorporated in the State of Texas in June 2002 and changed its state of incorporation to the State of Delaware in October 2008. Effective August 10, 2018, Teladoc, Inc. changed its corporate name to Teladoc Health, Inc. The Company’s principal executive office is located in Purchase, New York.</span></div>
tdoc Number Of Professional Associations Consolidated As Variable Interest Entities
NumberOfProfessionalAssociationsConsolidatedAsVariableInterestEntities
2 professional_association
tdoc Number Of Professional Corporations Consolidated As Variable Interest Entities
NumberOfProfessionalCorporationsConsolidatedAsVariableInterestEntities
10 professional_corporation
us-gaap Use Of Estimates
UseOfEstimates
<div style="padding-left:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="padding-left:9pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. The Company bases its estimates on historical experience, current business and economic factors, and various other assumptions that the Company believes are necessary to form a basis for making judgments about the carrying values of assets and liabilities, the recorded amounts of revenue and expenses, and the disclosure of contingent assets and liabilities. The Company is subject to uncertainties such as the impact of future events, economic and political factors, and changes in the Company’s business environment; therefore, actual results could differ from these estimates. Accordingly, the accounting estimates used in the preparation of the Company’s condensed consolidated financial statements will change as new events occur, as more experience is acquired, as additional information is obtained and as the Company’s operating environment evolves. The Company believes that estimates used in the preparation of these condensed consolidated financial statements are reasonable; however, actual results could differ materially from these estimates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in estimates are made when circumstances warrant. Such changes in estimates and refinements in estimation methodologies are reflected in the Condensed Consolidated Statements of Operations; if material, the effects of changes in estimates are disclosed in the Notes to Unaudited Condensed Consolidated Financial Statements. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and assumptions by management affect areas including the value and useful life of long-lived assets (including intangible assets), the value of goodwill, the capitalization and amortization of software development costs, deferred device and contract costs, allowances for sales and for doubtful accounts, and the accounting for business combinations. Other significant areas include revenue recognition (including performance guarantees and claims adjustments), the accounting for income taxes, contingencies, litigation and related legal accruals, the accounting for stock-based compensation awards, and other items as described in the Summary of Significant Accounting policies in this Quarterly Report and in the 2022 Form 10-K.</span></div>
CY2022Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
25091000 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
8307000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
660238000 usd
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
660238000 usd
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
112300000 usd
tdoc Contract With Customer Liability Period Increase Decrease
ContractWithCustomerLiabilityPeriodIncreaseDecrease
-1400000 usd
tdoc Contract With Customer Liability Period Increase Decrease
ContractWithCustomerLiabilityPeriodIncreaseDecrease
9300000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
88600000 usd
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
68200000 usd
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
65300000 usd
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
36100000 usd
CY2023Q3 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
31352000 usd
CY2022Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
29956000 usd
CY2023Q3 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
17999000 usd
CY2022Q4 tdoc Deferred Device Cost And Other Noncurrent
DeferredDeviceCostAndOtherNoncurrent
8404000 usd
CY2023Q3 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
49351000 usd
CY2022Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
38360000 usd
CY2022Q4 tdoc Deferred Device Cost And Other
DeferredDeviceCostAndOther
38360000 usd
tdoc Deferred Device Cost And Other Additions
DeferredDeviceCostAndOtherAdditions
45567000 usd
tdoc Deferred Device Cost And Other Cost Of Revenue Recognized
DeferredDeviceCostAndOtherCostOfRevenueRecognized
34576000 usd
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
12104000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
114782000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
130310000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
100248000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
344537000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
260330000 usd
CY2023Q3 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
7687000 usd
CY2022Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
6194000 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
35916000 usd
CY2022Q4 us-gaap Inventory Net
InventoryNet
56342000 usd
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
62248000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
63159000 usd
CY2023Q3 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
31352000 usd
CY2022Q4 tdoc Deferred Device Cost And Other Current
DeferredDeviceCostAndOtherCurrent
29956000 usd
CY2023Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
12875000 usd
CY2022Q4 us-gaap Goodwill
Goodwill
1073190000 usd
CY2023Q3 us-gaap Goodwill
Goodwill
1073190000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2538791000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
810489000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1728302000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2421251000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
584486000 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1836765000 usd
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
69189000 usd
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
48676000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
172210000 usd
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
148327000 usd
CY2023Q3 us-gaap Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
22645000 usd
CY2023Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
91834000 usd
CY2022Q3 us-gaap Adjustment For Amortization
AdjustmentForAmortization
58200000 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
231205000 usd
us-gaap Adjustment For Amortization
AdjustmentForAmortization
171503000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
199008000 usd
CY2023Q3 tdoc Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
824179000 usd
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1728302000 usd
CY2023Q3 tdoc Cloud Computing Costs Net
CloudComputingCostsNet
38200000 usd
CY2022Q4 tdoc Cloud Computing Costs Net
CloudComputingCostsNet
25400000 usd
CY2023Q3 tdoc Cloud Computing Expense
CloudComputingExpense
600000 usd
CY2022Q3 tdoc Cloud Computing Expense
CloudComputingExpense
600000 usd
tdoc Cloud Computing Expense
CloudComputingExpense
2400000 usd
tdoc Cloud Computing Expense
CloudComputingExpense
1100000 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
9235000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
10152000 usd
CY2023Q3 tdoc Accrued Consulting And Customer Service Fees Current
AccruedConsultingAndCustomerServiceFeesCurrent
17598000 usd
CY2023Q3 tdoc Performance Guarantees And Accrued Rebates Current
PerformanceGuaranteesAndAccruedRebatesCurrent
31615000 usd
CY2022Q4 tdoc Performance Guarantees And Accrued Rebates Current
PerformanceGuaranteesAndAccruedRebatesCurrent
18687000 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
5781000 usd
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
1480000 usd
CY2023Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
757000 usd
CY2022Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
3817000 usd
CY2023Q3 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
4662000 usd
CY2023Q3 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
5650000 usd
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
3247000 usd
CY2023Q3 tdoc Accrued Marketing And Advertising Current
AccruedMarketingAndAdvertisingCurrent
43078000 usd
CY2022Q4 tdoc Accrued Marketing And Advertising Current
AccruedMarketingAndAdvertisingCurrent
35055000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13592000 usd
CY2023Q3 tdoc Accrued Franchise And Sales Taxes Current
AccruedFranchiseAndSalesTaxesCurrent
17086000 usd
CY2022Q4 tdoc Accrued Franchise And Sales Taxes Current
AccruedFranchiseAndSalesTaxesCurrent
10183000 usd
CY2023Q3 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
4006000 usd
CY2022Q4 tdoc Other Current Liabilities Staff Augmentation
OtherCurrentLiabilitiesStaffAugmentation
3391000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
42298000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
46701000 usd
CY2023Q3 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
192553000 usd
CY2022Q4 tdoc Accrued Liabilities And Other Liabilities Excluding Accrued Compensation Current
AccruedLiabilitiesAndOtherLiabilitiesExcludingAccruedCompensationCurrent
168693000 usd
CY2023Q3 tdoc Debt Instrument Number Of Series Of Convertible Senior Debt Outstanding
DebtInstrumentNumberOfSeriesOfConvertibleSeniorDebtOutstanding
3 debtseries
CY2023Q3 us-gaap Restructuring Costs
RestructuringCosts
400000 usd
us-gaap Restructuring Costs
RestructuringCosts
16000000 usd
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
4043000 usd
us-gaap Restructuring Charges
RestructuringCharges
11180000 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
8251000 usd
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
6972000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
14658357 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4243934 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.79
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M6D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
19541000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
87554 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
24.27
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
171888 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
8.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2993000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
116323 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
50.27
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4043277 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
27.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M10D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
9600000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
4043277 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
27.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P5Y6M10D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
9600000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3053345 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
25.49
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y5M19D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
9600000 usd
CY2023Q3 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
400000 usd
CY2022Q3 tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
300000 usd
tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
1200000 usd
tdoc Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
24900000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
16848000 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.6558
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.5669
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.6795
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0113
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0346
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
52945000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55662000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
154708000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
167098000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
5028000 usd
CY2022Q3 us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
4561000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
14606000 usd
us-gaap Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount
EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
13404000 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
57973000 usd
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
60223000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
169314000 usd
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
180502000 usd
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
8993000 usd
CY2023Q3 us-gaap Restructuring Costs
RestructuringCosts
411000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2500000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2800000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1200000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2000000 usd
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2 segment
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
660238000 usd
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
611402000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1941888000 usd
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1769131000 usd
CY2023Q3 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
88757000 usd
CY2022Q3 tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
51211000 usd
tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
213677000 usd
tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
152419000 usd
tdoc Earnings Before Interest Taxes Depreciation And Amortization
EarningsBeforeInterestTaxesDepreciationAndAmortization
152419000 usd
CY2023Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
CY2022Q3 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 usd
us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
9630000000 usd
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
12606000 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
4803000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
33075000 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
6192000 usd
CY2023Q3 us-gaap Interest Expense
InterestExpense
5646000 usd
CY2022Q3 us-gaap Interest Expense
InterestExpense
6149000 usd
us-gaap Interest Expense
InterestExpense
16744000 usd
us-gaap Interest Expense
InterestExpense
17355000 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1792000 usd
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1571000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2908000 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2607000 usd
CY2023Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
94302000 usd
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
62008000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
239550000 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
180312000 usd
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
52945000 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
55662000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
154708000 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
167098000 usd
CY2023Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
5824000 usd
CY2022Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1594000 usd
CY2022Q3 us-gaap Restructuring Costs
RestructuringCosts
3677000 usd
us-gaap Restructuring Costs
RestructuringCosts
16043000 usd
us-gaap Restructuring Costs
RestructuringCosts
3677000 usd
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-59557000 usd
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-74647000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-194233000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-9851431000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2484000 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1171000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-2755000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1971000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-57073000 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-73476000 usd
us-gaap Net Income Loss
NetIncomeLoss
-191478000 usd
us-gaap Net Income Loss
NetIncomeLoss
-9849460000 usd
CY2023Q3 us-gaap Noncurrent Assets
NoncurrentAssets
32887000 usd
CY2022Q4 us-gaap Noncurrent Assets
NoncurrentAssets
29641000 usd

Files In Submission

Name View Source Status
0001477449-23-000066-index-headers.html Edgar Link pending
0001477449-23-000066-index.html Edgar Link pending
0001477449-23-000066.txt Edgar Link pending
0001477449-23-000066-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
R9999.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tdoc-20230930.htm Edgar Link pending
tdoc-20230930.xsd Edgar Link pending
tdoc-20230930xexx102.htm Edgar Link pending
tdoc-20230930xexx103.htm Edgar Link pending
tdoc-20230930xexx104.htm Edgar Link pending
tdoc-20230930xexx105.htm Edgar Link pending
tdoc-20230930xexx311.htm Edgar Link pending
tdoc-20230930xexx312.htm Edgar Link pending
tdoc-20230930xexx321.htm Edgar Link pending
tdoc-20230930xexx322.htm Edgar Link pending
tdoc-20230930_def.xml Edgar Link unprocessable
tdoc-20230930_cal.xml Edgar Link unprocessable
tdoc-20230930_lab.xml Edgar Link unprocessable
tdoc-20230930_pre.xml Edgar Link unprocessable
tdoc-20230930_htm.xml Edgar Link completed